Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Net Income (2020 - 2025)

Historic Net Income for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to -$7.6 million.

  • GeneDx Holdings' Net Income rose 814.49% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 10249.55%. This contributed to the annual value of -$52.3 million for FY2024, which is 7025.27% up from last year.
  • As of Q3 2025, GeneDx Holdings' Net Income stood at -$7.6 million, which was up 814.49% from $10.8 million recorded in Q2 2025.
  • GeneDx Holdings' Net Income's 5-year high stood at $32.7 million during Q3 2021, with a 5-year trough of -$308.7 million in Q4 2022.
  • Moreover, its 5-year median value for Net Income was -$40.2 million (2021), whereas its average is -$54.0 million.
  • Its Net Income has fluctuated over the past 5 years, first skyrocketed by 15781.33% in 2021, then tumbled by 66822.94% in 2022.
  • GeneDx Holdings' Net Income (Quarter) stood at -$40.2 million in 2021, then plummeted by 668.23% to -$308.7 million in 2022, then surged by 91.65% to -$25.8 million in 2023, then surged by 121.1% to $5.4 million in 2024, then tumbled by 240.4% to -$7.6 million in 2025.
  • Its Net Income was -$7.6 million in Q3 2025, compared to $10.8 million in Q2 2025 and -$6.5 million in Q1 2025.